pH-Responsive Ionizable Lipids for Low-Toxicity Lymph Node Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA delivery carriers, particularly lipid nanoparticles (LNPs), face challenges with high toxicity, liver aggregation, and inefficient targeted organ delivery, especially for lymph nodes, due to the use of cationic lipids that interact with cell membranes and trigger allergic reactions.
Innovation Solution
Development of an ionizable lipid with a specific structure, formulated into lipid nanoparticles, which maintains low toxicity and enhances delivery efficiency by optimizing organ targeting, particularly to lymph nodes, using a combination of auxiliary lipids and precise formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids with permanent positive charge are used as LNP components, then mRNA delivery efficiency is improved through interaction with negatively charged cell membranes, but toxicity and allergic reactions increase due to membrane instability and complement system activation
Solution Approach 1:
The patent applies parameter changes by transitioning from permanent cationic lipids to ionizable lipids that change their charge state based on pH. The ionizable lipids are neutral at physiological pH (reducing toxicity) but become cationic in the acidic endosomal environment (enhancing membrane interaction and mRNA delivery). This pH-dependent charge transformation resolves the contradiction between delivery efficiency and safety.
Solution Approach 2:
The patent employs dynamics by making the lipid charge property dynamic rather than static. The ionizable lipids dynamically adjust their charge state in response to pH changes during the delivery process: neutral in circulation (avoiding toxicity) and cationic in the endosome (facilitating membrane fusion and mRNA release). This dynamic behavior allows the system to optimize both safety and delivery efficiency at different stages.
2Object-affected harmful factors
If ionizable lipids are used to reduce toxicity, then safety is improved, but lymph node targeting efficiency remains insufficient with high liver aggregation
Solution Approach 1:
The patent applies local quality by introducing specific structural features (aromatic rings at positions 3 and/or 4 of the lipid backbone) that create localized regions of high affinity for lymph node uptake. These structural modifications are specifically positioned to interact with lymph node tissue characteristics, enabling selective accumulation in lymph nodes while maintaining the overall safety profile of ionizable lipids.
Solution Approach 2:
The patent employs composite materials by combining ionizable lipids with specific aromatic ring structures and other LNP components (phospholipids, cholesterol, PEG-lipids) to create a synergistic formulation. The aromatic rings provide lymph node targeting capability while the ionizable lipid backbone maintains safety, and the composite LNP structure optimizes both properties simultaneously.
3Manufacturing precision
If LNP formulation is optimized for organ targeting, then delivery precision to target tissues is improved, but formulation complexity increases due to multiple component optimization requirements
Solution Approach 1:
The patent applies segmentation by dividing the LNP formulation into distinct functional components: ionizable lipids with aromatic rings for lymph node targeting, phospholipids for membrane structure, cholesterol for stability, and PEG-lipids for circulation. Each component has a specific function, and their modular combination allows for precise control over delivery characteristics without requiring complete redesign of the entire formulation system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ionizable lipid formulation achieves high safety and efficient lysosomal escape, improving therapeutic efficacy by reducing systemic toxicity and enhancing targeted drug delivery to lymph nodes.
Implementation Method 1
Ionizable lipids will undergo protonation and conversion to cationic lipids at low pH values
Implementation Method 2
Ionizable lipids are not charged under physiological pH conditions
Implementation Method 3
LNP to escape and release mRNA into the cytoplasm through proton sponge effect and membrane fusion mechanism
Data Source
Figure 1~2
Figure 3~4
Figure 5~7
AI summary
Provided in the present invention are an ionizable lipid, and a drug delivery system containing the ionizable lipid. Specifically, provided in the present invention is an ionizable lipid having the structure of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.